Gastric Cancer Education
Gastric and gastroesophageal junction cancer treatment increasingly depends on biomarker-driven strategies including HER2, PD-L1, and Claudin 18.2. Knowledge Med sessions help community providers build confidence in this evolving landscape through case-based learning.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing gastric & gej cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Applying HER2, PD-L1 CPS, and MSI testing to guide therapy
- Integrating immunotherapy with chemotherapy in first-line treatment
- Selecting second-line therapy based on molecular profile
- Managing perioperative treatment for resectable disease
What Sessions Cover
Knowledge Med Gastric & GEJ Cancer sessions use interactive case simulations to address these topics and more.
- Biomarker-driven first-line therapy in advanced gastric/GEJ cancer
- HER2-targeted approaches: trastuzumab, T-DXd, and combinations
- Immunotherapy in MSI-H and PD-L1-high gastric cancer
- Emerging targets: Claudin 18.2, FGFR2, and beyond
Interactive Gastric & GEJ Cancer Sessions
Case Simulations
Work through realistic gastric & gej cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key Gastric & GEJ Cancer clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a Gastric & GEJ Cancer Session
Third-party, non-promotional gastric & gej cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session